Johnson & Johnson (NYSE:JNJ) Stock Price Down 1.1% - Time to Sell?

Key Points

• Johnson & Johnson's stock price fell by 1.1% to $190.38, with trading volume down by 23% compared to its average.
• Wall Street analysts have a consensus rating of “Moderate Buy” for the stock, with an average price target of $199.05, reflecting optimism despite the recent price drop.
• The company declared a quarterly dividend of $1.30 per share, with a dividend yield of 2.7%, reinforcing its commitment to returning value to shareholders.

Johnson & Johnson (NYSE:JNJ - Get Free Report)'s stock price was down 1.1% during mid-day trading on Friday . The stock traded as low as $189.42 and last traded at $190.38. Approximately 6,846,087 shares changed hands during mid-day trading, a decline of 23% from the average daily volume of 8,902,778 shares. The stock had previously closed at $192.47.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on JNJ shares. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Wall Street Zen raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Bank of America raised their price objective on Johnson & Johnson from $198.00 to $204.00 and gave the company a "neutral" rating in a research note on Wednesday, October 15th. Daiwa Capital Markets raised Johnson & Johnson from a "neutral" rating to an "outperform" rating and set a $203.00 price objective for the company in a research note on Monday. Finally, Guggenheim raised Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price objective for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $199.05.

Johnson & Johnson Price Performance

The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $458.51 billion, a P/E ratio of 18.38, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The stock has a 50 day moving average of $181.99 and a 200-day moving average of $165.84.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson's dividend payout ratio (DPR) is currently 50.19%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.16% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Apexium Financial LP increased its holdings in Johnson & Johnson by 10.7% during the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company's stock worth $3,978,000 after purchasing an additional 2,310 shares during the period. Avanza Fonder AB increased its holdings in Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company's stock worth $35,842,000 after purchasing an additional 6,566 shares during the period. Joel Isaacson & Co. LLC increased its holdings in Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after purchasing an additional 2,526 shares during the period. Tokio Marine Asset Management Co. Ltd. increased its holdings in shares of Johnson & Johnson by 7.0% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock valued at $12,164,000 after acquiring an additional 4,816 shares during the period. Finally, Klingman & Associates LLC increased its holdings in shares of Johnson & Johnson by 13.4% in the 1st quarter. Klingman & Associates LLC now owns 16,984 shares of the company's stock valued at $2,817,000 after acquiring an additional 2,005 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.